Article
CAR-T Cell Therapy in Cancer Treatment
IQVIA Ark Patent Intelligence
Mar 25, 2024

Cancer is a multifaceted illness that is expanding rapidly and stands as the second primary cause of death worldwide. It is marked by the uncontrolled proliferation of abnormal cells that may infiltrate or metastasise to other parts of the body. Current cancer treatments encompass pharmaceuticals or chemotherapy, radiation therapy, and surgical procedures. Chimeric antigen receptor (CAR)-T cell therapy is a novel form of treatment that is emerging as a transformative approach in cellular immunotherapy. In 2021, the global market for CAR-T cell therapy was estimated to be 1.5 billion USD and it is forecasted to grow to approximately 7.6 billion USD by 2026, demonstrating a compound annual growth rate (CAGR) of 39.1%. Concurrently, the number of CAR-T clinical trials is on the rise, with continual improvements to the CAR-T constructs aimed at boosting their effectiveness and minimising adverse outcomes. 2 The therapeutic promise has stirred an interest in patent filings protecting CAR technology all over the globe. As per Ark Patent Intelligence data, patent filings have significantly increased in the last few years, starting with a mere 10 key patent filings in 1992 and this figure has now surpassed 500 key patents filed worldwide.

Please fill in your details on the left to download the article.

Related solutions

Contact Us